Section Arrow
Quote
ARQT.NASDAQ
- Arcutis Biotherapeutics
Quotes are at least 15-min delayed:2024/05/16 00:01 EDT
Last
 9.24
+1.11 (+13.65%)
Day High 
10.13 
Prev. Close
8.13 
1-M High
10.465 
Volume 
13.90M 
Bid
9.14
Ask
9.23
Day Low
8.9 
Open
9.42 
1-M Low
7.47 
Market Cap 
939.22M 
Currency USD 
P/E -- 
%Yield 0 
10-SMA 8.12 
20-SMA 8.53 
50-SMA 9.71 
52-W High 13.17 
52-W Low 1.76 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.78/--
Enterprise Value
1.14B
Balance Sheet
Book Value Per Share
0.77
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
59.61M
Operating Revenue Per Share
0.42
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
DNAGinkgo Bioworks Holdings0.8391-0.0237-2.75%-- 
NVAXNovavax12.9-0.58-4.30%-- 
JAGXJaguar Health0.2551-0.0198-7.20%-- 
OCGNOcugen1.96+0.26+15.29%-- 
ARQTArcutis Biotherapeutics9.24+1.11+13.65%-- 
Quotes are at least 15-min delayed：2024/05/16 00:01 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.